成人用ワクチンの世界市場レポート 2025年

成人用ワクチンの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.5％で352億2,000万米ドルに成長します。予測期間における成長は、新たな感染脅威の出現、予防接種登録への注目の高まり、抗菌薬耐性の脅威の高まり、パンデミック対策への世界の取り組み、個別化ワクチンへのシフト、妊産婦への予防接種への注目の高まりなどに起因すると考えられます。予測期間における主な動向としては、デジタルヘルスの統合、ワクチン製造の技術進歩、政府と製薬企業間の協力、ワクチン送達技術の進歩、予防接種プログラムの拡大などが挙げられます。

伝染性疾患の発生率の上昇が成人用ワクチン市場を前進させています。伝染病とは、人から人へ感染する病気です。ワクチンは、これらの病気に対する免疫の獲得を可能にし、感染症に対抗する非常に効果的な手段となっています。例えば、2023年3月、米国に本部を置く国立公衆衛生機関である疾病対策予防センター（Centers for Disease Control and Prevention）は、2022年の国内の結核患者数は8,300人で、2021年の7,874人から増加したと報告しました。2022年の結核罹患率は10万人あたり2.5人と、2021年の2.4人からわずかに上昇しました。したがって、伝染性疾患の有病率の増加が成人用ワクチン市場の成長を牽引しています。

ヘルスケア支出の増加が成人用ワクチン市場の成長を後押ししています。ヘルスケア支出とは、国民に提供されるヘルスケアサービスに関連する全体的な費用を指します。ヘルスケア支出の増加は、しばしば医療研究開発のための資金増につながります。ワクチン接種プログラムに投資し、ワクチンへのアクセスを強化することで、ヘルスケアシステムは予防可能な疾病の負担を軽減し、人々の健康全体を改善することができます。さらに、成人へのワクチン接種は、ヘルスケアの利用を減らし、高額な治療の必要性を減らすことで、大幅なコスト削減につながります。例えば、2023年11月、カナダに本部を置く保健機関であるカナダ保健情報研究所は、2023年のカナダの総医療費は3,440億米ドルに達し、2022年と比較して90億米ドル以上増加すると予測しました。したがって、ヘルスケア支出の増加は、成人用ワクチン市場の成長にプラスの影響を与えています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の成人用ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の成人用ワクチン市場：成長率分析
• 世界の成人用ワクチン市場の実績：規模と成長, 2019-2024
• 世界の成人用ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の成人用ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の成人用ワクチン市場：ワクチン別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 一価
• 多価
• 世界の成人用ワクチン市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生弱毒化ワクチン
• 不活化ウイルスまたは細菌ワクチン
• トキソイドワクチン
• 組み換えワクチン
• 結合ワクチン
• 世界の成人用ワクチン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インフルエンザ
• DPT
• ヒトパピローマウイルス
• 帯状疱疹
• 肺炎球菌
• 肝炎
• 世界の成人用ワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘルスケア企業
• 病院
• 世界の成人用ワクチン市場：一価のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単一抗原ワクチン
• 特定の疾患に対するワクチン
• 世界の成人用ワクチン市場：多価のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 混合ワクチン
• 多抗原ワクチン

第7章 地域別・国別分析

• 世界の成人用ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の成人用ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 成人用ワクチン市場：競合情勢
• 成人用ワクチン市場：企業プロファイル
  • GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Pasteur Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • Commonwealth Serum Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Johnson & Johnson
• Serum Institute of India
• AstraZeneca PLC
• Novartis AG
• Protein Sciences Corporation
• Emergent BioSolutions Inc.
• Bavarian Nordic A/S
• Dynavax Technologies Corporation
• Novavax Inc
• Medimmune LLC
• BioNTech SE
• Moderna
• Inovio Pharmaceuticals
• Sinovac
• Valneva Se

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 成人用ワクチン市場2029：新たな機会を提供する国
• 成人用ワクチン市場2029：新たな機会を提供するセグメント
• 成人用ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Adult vaccines are immunizations administered to adults to stimulate an immune response against disease-causing pathogens. These vaccines play a crucial role in the prevention and treatment of various diseases affecting adults, including influenza, pneumococcal disease, and herpes.

The primary types of adult vaccines include monovalent and multivalent options. A monovalent vaccine contains the mRNA component of a single virus, triggering an immune response against a specific antigen. Various technologies are employed in the development of adult vaccines, including live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines. These vaccines find applications in preventing diseases such as influenza, diphtheria, pertussis, tetanus (dPT), human papillomavirus, shingles (zoster), pneumococcal disease, and hepatitis. Healthcare firms and hospitals are key users of these vaccines.

The adult vaccines market research report is one of a series of new reports from The Business Research Company that provides adult vaccines market statistics, including adult vaccines industry global market size, regional shares, competitors with a adult vaccines market share, detailed adult vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the adult vaccines industry. This adult vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adult vaccines market size has grown strongly in recent years. It will grow from $22.82 billion in 2024 to $24.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing aging population, government vaccination programs, growing awareness of preventive healthcare, vaccine development and innovation, public health campaigns.

The adult vaccines market size is expected to see strong growth in the next few years. It will grow to $35.22 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emergence of new infectious threats, increasing focus on immunization registries, rising threat of antimicrobial resistance, global efforts for pandemic preparedness, shift toward personalized vaccines, increased focus on maternal immunization. Major trends in the forecast period include digital health integration, technological advancements in vaccine production, collaborations between governments and pharmaceutical companies, advancements in vaccine delivery technologies, expanding immunization programs.

The rising incidence of contagious diseases is propelling the adult vaccine market forward. Contagious diseases are those that can be transmitted from one person to another. Vaccines enable individuals to develop immunity against these diseases, making them a highly effective means of combating infections. For example, in March 2023, the Centers for Disease Control and Prevention, a national public health agency based in the United States, reported that in 2022, there were 8,300 cases of tuberculosis in the country, an increase from 7,874 cases in 2021. The incidence of TB in 2022 rose slightly to 2.5 per 100,000 individuals, compared to 2.4 in 2021. Therefore, the increasing prevalence of contagious diseases is driving the growth of the adult vaccine market.

The rise in healthcare expenditure has bolstered the growth of the adult vaccine market. Healthcare expenditure refers to the overall costs associated with healthcare services provided to a population. An increase in healthcare spending often results in more funding for medical research and development. By investing in vaccination programs and enhancing access to vaccines, healthcare systems can alleviate the burden of preventable diseases and improve the overall health of the population. Moreover, adult vaccination can lead to substantial cost savings by decreasing healthcare utilization and the necessity for expensive treatments. For example, in November 2023, the Canadian Institute for Health Information, a health organization based in Canada, projected that Canada's total health expenditure in 2023 would reach $344 billion, representing an increase of over $9 billion compared to 2022. Therefore, the rise in healthcare expenditure has positively influenced the growth of the adult vaccine market.

Product innovation emerges as a pivotal trend driving the evolution of the adult vaccines market. Major industry players are introducing innovative products to fortify their market presence. For instance, in August 2022, GSK, a UK-based biopharma company, partnered with IQVIA, an India-based global provider of advanced analytics and clinical research services, to launch Vaccine Track. This pioneering data trend platform aims to enhance adult vaccination efforts nationwide by providing real-time, pertinent data trends that focus on improving public health initiatives. The advent of such innovative tools underscores the industry's commitment to leveraging data and technology to advance adult vaccination strategies and address prevailing healthcare challenges.

Prominent players within the adult vaccine market are emphasizing strategic collaborations aimed at the development and commercialization of personalized cancer vaccines. These collaborations, centered on mutual objectives, are pivotal business relationships between multiple companies. For instance, in October 2022, Merck & Co., Inc., an American multinational pharmaceutical company, partnered with Moderna, a US-based pharmaceutical and biotechnology company, to collectively advance and commercialize the personalized cancer vaccine mRNA-4157/V940. Under their existing collaboration and license agreement, both entities will collaborate on the development and commercialization of mRNA-4157/V940, which is currently undergoing assessment in a Phase 2 clinical trial conducted by Moderna. This vaccine is being evaluated alongside KEYTRUDA, Merck's anti-PD-1 therapy, as an adjuvant treatment for high-risk melanoma patients.

In August 2022, GSK, a UK-based pharmaceutical giant, acquired Affinivax, Inc., a US-based clinical-stage biopharmaceutical company, in a deal of undisclosed value. This strategic acquisition aligns with GSK's broader strategy of bolstering its portfolio in specialty medicines and vaccines, particularly focusing on innovative vaccine candidates for pneumococcal disease. Affinivax, Inc., known for its pioneering work in next-generation pneumococcal vaccines and adult vaccines based on the Multiple Antigen Presenting System (MAPS) platform technology, is expected to complement GSK's efforts in advancing cutting-edge vaccine solutions. This strategic move underscores GSK's commitment to driving advancements in adult vaccines and strengthening its position within the healthcare landscape.

Major companies operating in the adult vaccines market include GlaxoSmithKline PLC, Merck & Co, Sanofi Pasteur, Pfizer Inc, Commonwealth Serum Laboratories Limited, Johnson & Johnson, Serum Institute of India, AstraZeneca PLC, Novartis AG, Protein Sciences Corporation, Emergent BioSolutions Inc., Bavarian Nordic A/S, Dynavax Technologies Corporation, Novavax Inc, Medimmune LLC, BioNTech SE, Moderna, Inovio Pharmaceuticals, Sinovac, Valneva Se, Biological E Limited, Panacea Biotec, Shenzhen Kangtai Biological Products, Beijing Tiantan Biological Products, Hualan Biological Engineering, Chengdu Institute of Biological Products, Bharat Biotech International Limited, Takeda Pharmaceutical Company Limited

North America was the largest region in the adult vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the adult vaccines market during the forecast period. The regions covered in the adult vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the adult vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adult vaccines market consists of sales of mRNA vaccines and viral vector vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adult Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adult vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adult vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adult vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Monovalent; Multivalent
• 2) By Technology: Live Attenuated Vaccines; Inactivated Viral Or Bacterial Vaccines; Toxoid Vaccines; Recombinant Vaccines; Conjugate Vaccines
• 3) By Application: Influenza; DPT; Human Papillomavirus; Zoster; Pneumococcal; Hepatitis
• 4) By End Users: Healthcare Firms; Hospitals
• Subsegments:
• 1) By Monovalent: Single Antigen Vaccines; Specific Disease Vaccines
• 2) By Multivalent: Combination Vaccines; Multi-Antigen Vaccines
• Companies Mentioned: GlaxoSmithKline PLC; Merck & Co; Sanofi Pasteur; Pfizer Inc; Commonwealth Serum Laboratories Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adult Vaccines Market Characteristics

3. Adult Vaccines Market Trends And Strategies

4. Adult Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Adult Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adult Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adult Vaccines Market Growth Rate Analysis
• 5.4. Global Adult Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adult Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adult Vaccines Total Addressable Market (TAM)

6. Adult Vaccines Market Segmentation

• 6.1. Global Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent
• Multivalent
• 6.2. Global Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Vaccines
• Inactivated Viral or Bacterial Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Conjugate Vaccines
• 6.3. Global Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Influenza
• DPT
• Human Papillomavirus
• Zoster
• Pneumococcal
• Hepatitis
• 6.4. Global Adult Vaccines Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Healthcare Firms
• Hospitals
• 6.5. Global Adult Vaccines Market, Sub-Segmentation Of Monovalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Antigen Vaccines
• Specific Disease Vaccines
• 6.6. Global Adult Vaccines Market, Sub-Segmentation Of Multivalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Vaccines
• Multi-Antigen Vaccines

7. Adult Vaccines Market Regional And Country Analysis

• 7.1. Global Adult Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adult Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adult Vaccines Market

• 8.1. Asia-Pacific Adult Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adult Vaccines Market

• 9.1. China Adult Vaccines Market Overview
• 9.2. China Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adult Vaccines Market

• 10.1. India Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adult Vaccines Market

• 11.1. Japan Adult Vaccines Market Overview
• 11.2. Japan Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adult Vaccines Market

• 12.1. Australia Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adult Vaccines Market

• 13.1. Indonesia Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adult Vaccines Market

• 14.1. South Korea Adult Vaccines Market Overview
• 14.2. South Korea Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adult Vaccines Market

• 15.1. Western Europe Adult Vaccines Market Overview
• 15.2. Western Europe Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adult Vaccines Market

• 16.1. UK Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adult Vaccines Market

• 17.1. Germany Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adult Vaccines Market

• 18.1. France Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adult Vaccines Market

• 19.1. Italy Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adult Vaccines Market

• 20.1. Spain Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adult Vaccines Market

• 21.1. Eastern Europe Adult Vaccines Market Overview
• 21.2. Eastern Europe Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adult Vaccines Market

• 22.1. Russia Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adult Vaccines Market

• 23.1. North America Adult Vaccines Market Overview
• 23.2. North America Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adult Vaccines Market

• 24.1. USA Adult Vaccines Market Overview
• 24.2. USA Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adult Vaccines Market

• 25.1. Canada Adult Vaccines Market Overview
• 25.2. Canada Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adult Vaccines Market

• 26.1. South America Adult Vaccines Market Overview
• 26.2. South America Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adult Vaccines Market

• 27.1. Brazil Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adult Vaccines Market

• 28.1. Middle East Adult Vaccines Market Overview
• 28.2. Middle East Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adult Vaccines Market

• 29.1. Africa Adult Vaccines Market Overview
• 29.2. Africa Adult Vaccines Market, Segmentation By Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adult Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adult Vaccines Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adult Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Adult Vaccines Market Competitive Landscape
• 30.2. Adult Vaccines Market Company Profiles
  • 30.2.1. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi Pasteur Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Commonwealth Serum Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis

31. Adult Vaccines Market Other Major And Innovative Companies

• 31.1. Johnson & Johnson
• 31.2. Serum Institute of India
• 31.3. AstraZeneca PLC
• 31.4. Novartis AG
• 31.5. Protein Sciences Corporation
• 31.6. Emergent BioSolutions Inc.
• 31.7. Bavarian Nordic A/S
• 31.8. Dynavax Technologies Corporation
• 31.9. Novavax Inc
• 31.10. Medimmune LLC
• 31.11. BioNTech SE
• 31.12. Moderna
• 31.13. Inovio Pharmaceuticals
• 31.14. Sinovac
• 31.15. Valneva Se

32. Global Adult Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adult Vaccines Market

34. Recent Developments In The Adult Vaccines Market

35. Adult Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Adult Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adult Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adult Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer